Compassionate-use pilot study shows potential in hereditary angioedema treatment
A compassionate-use pilot study evaluated the impact of IONIS-PKK-LRx (a ligand-conjugated antisense oligonucleotide designed for receptor-mediated delivery to hepatocytes) on 2 patients with severe bradykinin-mediated angioedema, according to results published in New England Journal of Medicine.
Hereditary angioedema is a rare disorder that results in severe recurrent swelling.
The patients were treated for 12-16 weeks with weekly subcutaneous injections of the unconjugated parent drug, IONIS-PKKRx. After the initial period, patients were given IONIS-PKK-LRx (80 mg) every 3-4 weeks for 7 to 8 months.
Patients saw a reduction in the angioedema attack rate.
Read the full study here.
Cohn DMC, Viney NJ, Fijen LM, et al. Antisense inhibition of prekallikrein to control hereditary angioedema.
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809